Prospective multicentre study of the U-SENS test method for skin sensitization testing. Issue 1 (25th December 2015)

• Record Type: Journal Article
• Authors: Alépée, N.; Piroird, C.; Aujoulat, M.; Dreyfuss, S.; Hoffmann, S.; Hohenstein, A.; Meloni, M.; Nardelli, L.; Gerbeix, C.; Cotovio, J.
• Is Part Of: Toxicology in vitro. Volume 30:Issue 1 Part B(2015)
• Page Start: 373
• Page End: 382
• Publication Date: 2015-12-25
• Subjects: AOP Adverse Outcome Pathway -- BLR between-laboratory reproducibility -- CV cell viability -- DPRA Direct Peptide Reactivity Assay -- DMSO dimethyl sulfoxide -- EC effective concentration -- EURL-ECVAM European Union Reference Laboratory for alternatives to animal testing -- EU European Union -- GLP Good Laboratory Practice -- h-CLAT human Cell Line Activation Test -- IATA Integrated approaches to Testing and Assessment -- ITS Integrated Testing Strategies -- LLNA Local Lymph Node Assay -- OECD Organization for Economic Co-operation and Development -- REACH Registration, Evaluation, Authorization and Restriction of Chemicals -- RPMI Roswell Park Memorial Institute medium -- WLR within-laboratory reproducibility; Skin sensitisation -- U-SENS™ -- Reproducibility -- In vitro test method -- Predictivity -- Validation; Toxicity testing -- In vitro -- Periodicals; Toxicology -- Periodicals; 615.9
• DOI: 10.1016/j.tiv.2015.09.028
• Languages: English
• ISSNs: 0887-2333

Abstract

Abstract: The U-SENS™ is a test method based on the human myeloid U937 cell line to assess the skin sensitisation potential of substances. To demonstrate its robustness, a multicentre validation study with four laboratories testing 24 coded substances has been conducted according to internationally agreed principles. The primary objective of the study was to enlarge the U-SENS™'s reproducibility database. Secondary objectives were to provide additional evidence on its transferability and its predictive capability. Reproducibility within laboratories was approximately 92%, while the reproducibility between laboratories was 87.5%. Predictivity for the 24 validation substances was high, with sensitivity, specificity and accuracy being on average at least 93.8%. Similar performances are obtained for 38 substances when combining the study results with those of an earlier multicentre study, as well as with an automated version of the U-SENS™. With reliability and relevance similar to comparable non-animal skin sensitisation test methods, which have achieved regulatory acceptance, it is concluded that the U-SENS™ is a well reproducible and predictive test method. This profiles the U-SENS™ as a valuable addition to the suite of non-animal testing methods for skin sensitisation with the potential to significantly contribute to the development of integrated testing strategies. Highlights: The Myeloid U937 Skin Sensitization Test (U-SENS™) addresses dendritic cell response's key event. A validation study has been conducted with four laboratories on 24 substances. Reproducibility within laboratories was 91.7%. Reproducibility between laboratories was 87.5% (21/24 substances). Overall 38 chemicals tested in the 2 multicentre studies gave similar performances.